» Articles » PMID: 21054173

Antiestrogens and Their Therapeutic Applications in Breast Cancer and Other Diseases

Overview
Journal Annu Rev Med
Publisher Annual Reviews
Specialty General Medicine
Date 2010 Nov 9
PMID 21054173
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The identification of the link between breast cancer and estrogens has led to the development of antiestrogens, in particular tamoxifen, to inhibit the activities of estrogen receptors (ERs) in breast cancer cells. The clinical use of tamoxifen has played a major part in decreasing breast cancer mortality over the past 30 years. Though antiestrogenic in the breast, some antiestrogens have estrogen-like actions in other tissues, acting to promote bone density and protect against cardiovascular disease, thus raising the possibility of their use in counteracting the effects of estrogen loss following menopause. Moreover, antiestrogens show efficacy as chemopreventive agents in women at high risk of developing breast cancer. Thus, antiestrogens define an important and well-understood class of cancer drug, which continue to be a mainstay in breast cancer treatment.

Citing Articles

Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function.

Belluti S, Imbriano C, Casarini L Cancers (Basel). 2023; 15(18).

PMID: 37760622 PMC: 10526871. DOI: 10.3390/cancers15184653.


anticancer activity of extract on mcf-7 breast cancer cell lines.

Sabu A, J S, R G, E D Bioinformation. 2023; 19(1):43-47.

PMID: 37720282 PMC: 10504496. DOI: 10.6026/97320630019043.


Phytoestrogen-derived multifunctional ligands for targeted therapy of breast cancer.

Zhang Y, Pan H, Yu C, Liu R, Xing B, Jia B Asian J Pharm Sci. 2023; 18(4):100827.

PMID: 37588993 PMC: 10425851. DOI: 10.1016/j.ajps.2023.100827.


Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.

Fernandez-Garcia D, Nteliopoulos G, Hastings R, Rushton A, Page K, Allsopp R Br J Cancer. 2022; 127(10):1858-1864.

PMID: 36088510 PMC: 9643413. DOI: 10.1038/s41416-022-01962-9.


CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope.

Karn V, Sandhya S, Hsu W, Parashar D, Singh H, Jha N Cancer Cell Int. 2022; 22(1):234.

PMID: 35879772 PMC: 9316746. DOI: 10.1186/s12935-022-02654-3.